Mitochondrial dysfunction, a hallmark of neurodegenerative diseases, is improved by SGLT-2 inhibitors, which enhance mitochondrial biogenesis and reduce oxidative stress. This evidence concerns the gene SLC5A2 and neurodegenerative disease.